A citation-based method for searching scientific literature

Yiting Dong, Jiachen Xu, Boyang Sun, Jie Wang, Zhijie Wang. Mol Diagn Ther 2022
Times Cited: 5







List of co-cited articles
17 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
159
60

Targeting un-MET needs in advanced non-small cell lung cancer.
Niamh Coleman, Alice Harbery, Sara Heuss, Igor Vivanco, Sanjay Popat. Lung Cancer 2022
5
40

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
261
40

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer.
Lingzhi Hong, Jianjun Zhang, John V Heymach, Xiuning Le. Ther Adv Med Oncol 2021
18
40

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Shun Lu, Jian Fang, Xingya Li, Lejie Cao, Jianying Zhou, Qisen Guo, Zongan Liang, Ying Cheng, Liyan Jiang, Nong Yang,[...]. Lancet Respir Med 2021
38
40

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges.
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Lung Cancer (Auckl) 2021
8
40

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Bob T Li, Egbert F Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas N Saltos, Enriqueta Felip,[...]. N Engl J Med 2022
99
40

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.
Juan Esteban Garcia-Robledo, Rafael Rosell, Alejandro Ruíz-Patiño, Carolina Sotelo, Oscar Arrieta, Lucia Zatarain-Barrón, Camila Ordoñez, Elvira Jaller, Leonardo Rojas, Alessandro Russo,[...]. Ther Adv Respir Dis 2022
2
100


Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
65
40

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
390
40


Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Monica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, Wenjing Zhu, Kaumudi Bhawe, Nerissa Mendoza, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Ling Fu,[...]. Cancer Res 2006
352
40

Understanding and targeting resistance mechanisms in NSCLC.
Julia Rotow, Trever G Bivona. Nat Rev Cancer 2017
463
40

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Alessandro Leonetti, Sugandhi Sharma, Roberta Minari, Paola Perego, Elisa Giovannetti, Marcello Tiseo. Br J Cancer 2019
388
40

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
Joost Neijssen, Rosa M F Cardoso, Kristen M Chevalier, Luus Wiegman, Thomas Valerius, G Mark Anderson, Sheri L Moores, Janine Schuurman, Paul W H I Parren, William R Strohl,[...]. J Biol Chem 2021
34
40

Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal.
David M Phillippo, Anthony E Ades, Sofia Dias, Stephen Palmer, Keith R Abrams, Nicky J Welton. Med Decis Making 2018
118
20

Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.
Conor E Steuer, Madhusmita Behera, Yuan Liu, Chao Fu, Theresa W Gillespie, Nabil F Saba, Dong M Shin, Rathi N Pillai, Suchita Pakkala, Taofeek K Owonikoko,[...]. Clin Lung Cancer 2017
41
20

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.
Nagla Abdel Karim, James Schuster, Ihab Eldessouki, Ola Gaber, Tariq Namad, Jiang Wang, Changchun Xie, John C Morris. Oncotarget 2017
32
20

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Leylah M Drusbosky, Richa Dawar, Estelamari Rodriguez, Chukwuemeka V Ikpeazu. J Hematol Oncol 2021
9
20

MEK inhibitors for the treatment of non-small cell lung cancer.
Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li, Qiming Wang. J Hematol Oncol 2021
49
20

Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research.
James E Signorovitch, Vanja Sikirica, M Haim Erder, Jipan Xie, Mei Lu, Paul S Hodgkins, Keith A Betts, Eric Q Wu. Value Health 2012
179
20

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.
Patricia Guyot, A E Ades, Mario J N M Ouwens, Nicky J Welton. BMC Med Res Methodol 2012
996
20

Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.
Paula Chu, Miranta Antoniou, Mohit K Bhutani, Amine Aziez, Monica Daigl. J Comp Eff Res 2020
5
20

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
750
20

A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC.
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi. Cancers (Basel) 2020
8
20

Simulation and matching-based approaches for indirect comparison of treatments.
K Jack Ishak, Irina Proskorovsky, Agnes Benedict. Pharmacoeconomics 2015
41
20

Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi. Lung Cancer 2021
6
20

Savolitinib: First Approval.
Anthony Markham. Drugs 2021
15
20

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim,[...]. Lancet Oncol 2012
944
20

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
287
20

FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC.
Sisi Cao, Zhuo Wang, Xiujuan Gao, Wenjuan He, Yue Cai, Hui Chen, Rong Xu. J Exp Clin Cancer Res 2018
51
20

Impact of Targeted Therapy on the Survival of Patients With Advanced-Stage Non-small Cell Lung Cancer in Oncosalud - AUNA.
Alfredo Aguilar, Luis Mas, Daniel Enríquez, Carlos Vallejos, Rosa Gutarra, Claudio J Flores. Cancer Control 2022
1
100

Artificial Intelligence and its future potential in lung cancer screening.
Christopher Joy Mathew, Ashwini Maria David, Chris Mariya Joy Mathew. EXCLI J 2020
5
20

Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
Xiya Ma, Shaoxing Yang, Kun Zhang, Jing Xu, Panpan Lv, Hongjun Gao, Haifeng Qin, Hong Wang, Xiaoqing Liu. Thorac Cancer 2022
2
50


PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
Minghui Zhang, Guoliang Li, Yanbo Wang, Yan Wang, Shu Zhao, Pu Haihong, Hongli Zhao, Yan Wang. Sci Rep 2017
129
20

Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review.
Stepan M Esagian, Georgia Ι Grigoriadou, Ilias P Nikas, Vasileios Boikou, Peter M Sadow, Jae-Kyung Won, Konstantinos P Economopoulos. J Cancer Res Clin Oncol 2020
35
20

Lung Cancer Biomarkers.
Pamela Villalobos, Ignacio I Wistuba. Hematol Oncol Clin North Am 2017
104
20

Inhibition of Nuclear Factor Kappa B as a Therapeutic Target for Lung Cancer.
Mengjie Li, Peng Liu, Biao Wang, Jie Zhou, Jian Yang. Altern Ther Health Med 2022
1
100

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).
Solange Peters, Enriqueta Felip, Urania Dafni, Amanda Tufman, Matthias Guckenberger, Ruth Álvarez, Ernest Nadal, Annemarie Becker, Hansjörg Vees, Miklos Pless,[...]. J Thorac Oncol 2021
37
20

An updated patent review of small-molecule ROS1 kinase inhibitors (2015-2021).
Meng Liu, Jintian Dai, Mudan Wei, Qingshan Pan, Wufu Zhu. Expert Opin Ther Pat 2022
1
100

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Claudia Fumarola, Mara A Bonelli, Pier Giorgio Petronini, Roberta R Alfieri. Biochem Pharmacol 2014
299
20

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.
Howard Jack West, Mark McCleland, Federico Cappuzzo, Martin Reck, Tony Sk Mok, Robert M Jotte, Makoto Nishio, Eugene Kim, Stefanie Morris, Wei Zou,[...]. J Immunother Cancer 2022
9
20


Time spans from first symptom to treatment in patients with lung cancer--the influence of symptoms and demographic characteristics.
Malin Lövgren, Helena Leveälahti, Carol Tishelman, Sara Runesdotter, Katarina Hamberg. Acta Oncol 2008
29
20

Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC.
John F Roller, Nirmal K Veeramachaneni, Jun Zhang. Cancers (Basel) 2022
4
25

Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy.
Yan Li, Chen Yang, Zhicheng Liu, Shangce Du, Susan Can, Hailin Zhang, Linmeng Zhang, Xiaowen Huang, Zhenyu Xiao, Xiaobo Li,[...]. Mol Cancer 2022
4
25

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
Michael R Shafique, Terrence L Fisher, Elizabeth E Evans, John E Leonard, Desa Rae E Pastore, Crystal L Mallow, Ernest Smith, Vikas Mishra, Andreas Schröder, Kevin M Chin,[...]. Clin Cancer Res 2021
5
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.